Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8299163 | 0.72 | CYP1A2 (0.34) | KMT2ACYP1A2ESR1ESR2ENPP2 | |
| SCHEMBL363322 | 0.71 | CA1 (0.43) | KMT2ARAB9AHPGDENPP2MAPT | |
| SCHEMBL5561238 | 0.69 | MAPT (0.42) | KMT2ARAB9ACYP1A2MAPTPOLB | |
| SCHEMBL13644473 | 0.69 | ALDH1A1 (0.48) | ALOX15ENPP2 | |
| SCHEMBL4654782 | 0.68 | ALOX5 (0.49) | KMT2AHPGDMAPTPOLBNR1H4 | |
| SCHEMBL763540 | 0.68 | CA12 (0.47) | KMT2AMAPTPOLBNPC1SMN1; SMN2 | |
| SCHEMBL29950690 | 0.68 | CA12 (0.47) | KMT2AMAPTPOLBNPC1SMN1; SMN2 | |
| SCHEMBL362047 | 0.67 | CES2 (0.41) | CYP1A2NR1H4 | |
| SCHEMBL29689051 | 0.67 | CES2 (0.41) | CYP1A2NR1H4 | |
| SCHEMBL28616192 | 0.67 | TSHR (0.53) | MAPK1CYP1A2ESR1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682076-A4 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS INC (US) | 2008-02-06 | — | — | EP | disclosed |
| US-7183267-B2 | β-lactamase inhibitors and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183267-B2 | β-lactamase inhibitors and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183267-B2 | β-lactamase inhibitors and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1682076-A2 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | Fulcrum Pharmaceuticals, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1635812-A2 | BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | Fulcrum Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050267071-A1 | Inhibitors of coronavirus protease and methods of use thereof | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| US-20050124580-A1 | Beta-lactamase inhibitors and methods of use thereof | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2005041904-A2 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005041904-A2 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005004799-A2 | β-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267071-A1 | Inhibitors of coronavirus protease and methods of use thereof | ACE, ACE2, CTRL | KMT2A 3018/4885RAB9A 3194/4885HPGD 3235/4885 |
| US-20050124580-A1 | Beta-lactamase inhibitors and methods of use thereof | LCT, BCHE, GAA | KMT2A 1341/4885RAB9A 1236/4885HPGD 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.